NorthCrest Asset Manangement LLC Buys 557 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

NorthCrest Asset Manangement LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.9% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 11,903 shares of the biopharmaceutical company's stock after purchasing an additional 557 shares during the period. NorthCrest Asset Manangement LLC's holdings in Regeneron Pharmaceuticals were worth $7,549,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Rockland Trust Co. purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $255,000. Net Worth Advisory Group lifted its holdings in Regeneron Pharmaceuticals by 1.4% during the 1st quarter. Net Worth Advisory Group now owns 1,708 shares of the biopharmaceutical company's stock worth $1,083,000 after purchasing an additional 24 shares in the last quarter. Greenwood Capital Associates LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at about $5,354,000. Simon Quick Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 13.0% in the 1st quarter. Simon Quick Advisors LLC now owns 1,150 shares of the biopharmaceutical company's stock valued at $730,000 after acquiring an additional 132 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Regeneron Pharmaceuticals by 171.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock valued at $305,311,000 after acquiring an additional 303,785 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on REGN. Wells Fargo & Company cut Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and lowered their price target for the company from $700.00 to $580.00 in a report on Friday, May 30th. Wall Street Zen cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Guggenheim reaffirmed a "buy" rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. The Goldman Sachs Group lowered their price target on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Finally, JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $836.48.

Regeneron Pharmaceuticals Trading Up 1.4%

Shares of Regeneron Pharmaceuticals stock traded up $7.40 on Friday, hitting $529.24. The stock had a trading volume of 951,512 shares, compared to its average volume of 877,247. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The stock has a market cap of $57.14 billion, a price-to-earnings ratio of 13.83, a PEG ratio of 2.34 and a beta of 0.31. The stock's 50-day simple moving average is $563.19 and its two-hundred day simple moving average is $649.98.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm's revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $9.55 EPS. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.67%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.